Intensity Therapeutics shares more than double on promising cancer trial data

Intensity Therapeutics

30/10/2025 15:38

Updates

** Intensity Therapeutics's shares INTS.O soar 183.6% to $0.75 - on track for its best one-day percentage gain

** Co's experimental cancer drug, INT230-6, showed encouraging results in patients with advanced cancers, according to a study published in Lancet's eBioMedicine

** INTS says INT230-6 showed 75% disease control rate in advanced cancers - study data

** Drug injected directly into tumors; shrank untreated tumors in 20% of patients, co says

** Co says median survival was 11.9 months overall, while it was 21.3 months in sarcoma patients

**  Including session's move, stock was down ~56% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))